Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Microbiologics Acquires Phthisis Diagnostics, New Direction Exhibited at Current Meeting of the Association for Molecular Pathology

By LabMedica International staff writers
Posted on 11 Nov 2013
Phthisis Diagnostics (Charlottesville, VA, USA) has announced its acquisition by Microbiologics (St. More...
Cloud, MN, USA) to establish Phthisis’ technology as the foundation for a new division at Microbiologics.

Pthisis’ patented “G-Sphere” molecular standards product line will be the foundation for Microbiologics’ launch into molecular products and for the new division it is forming. G-Sphere standards are synthetic genes that provide easy-to-use, safe, stable, consistent, and abundant controls for virtually any organism or molecular assay. Currently, Microbiologics produces an array of lyophilized microorganism products in convenient, ready-to-use formats for quality control of microbiological testing.

Crystal Icenhour, PhD, adjunct assistant professor of infectious diseases at Duke University Medical Center, and President and Chief Science Officer at Phthisis since 2006, along with her research team, created the new technology. She will serve as an advisor with Microbiologics during the adoption of Phthisis’ technology and development of their new division. “We introduced this product line about a year ago to provide much needed quality control standards to molecular laboratories. I am pleased that this longer established company will have the structure to take these products much further than our smaller company could have,” said Prof. Icenhour.

Brad Goskowicz, Microbiologics CEO, commented, “These innovative molecular standards will lay the foundation for Microbiologics to design and launch a broad collection of molecular products and custom services. It will expand our range of biomaterials to include viruses and other hard to grow microorganisms.”

Microbiologics is adding Brian Beck, PhD in bacteriology, to its senior management team as Vice President of Molecular Products and Services. Dr. Beck has spent the last ten years at ATCC in Virginia where he managed the Microbiology Collection and Associated BioServices. “I’m quite excited to extend what Microbiologics has done with their culture business and bring that same practical, user-friendly format to the molecular diagnostic business,” said Dr. Beck.

To commence their new initiative, Microbiologics is exhibiting at the Association for Molecular Pathology (AMP) annual meeting, November 14-16, 2013, Phoenix (Arizona, USA).

Related Links:

Phthisis Diagnostics
Microbiologics



Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Pipette Controller
Sapphire MaxiPette
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.